US 11,168,058 B2
MANUFACTURE OF A CRYSTALLINE PHARMACEUTICAL PRODUCT
Log In
Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

General

US 11,168,058 B2
MANUFACTURE OF A CRYSTALLINE PHARMACEUTICAL PRODUCT
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Karen Cheng
Art Unit:
1626 Organic Chemistry
Inventors:
Merja REUNANEN; Anna STAFFANS
Priority:
02/27/18
Filed:
09/06/19
Granted:
11/09/21
Expiration:
02/27/38
Abstract
The present disclosure relates to crystalline particles of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m2/g, preferably from about 10 to about 15 m2/g, and to the method for the preparation of such particles. Compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.
Cooperative Patent Classification (CPC)
C07C07D231/14C07DA61P35/00A61K45/06A61P

Analytics

Cases

Patent Assignments

Citations